FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject	,
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last)	(Fir	1. Name and Address of Reporting Person* ZDRAVESKI ZORAN					2. Issuer Name and Ticker or Trading Symbol TScan Therapeutics, Inc. [TCRX]									tionship of Reportir all applicable) Director Officer (give title		10% O	wner	
(Last) (First) (Middle) C/O TSCAN THERAPEUTICS, INC. 830 WINTER STREET					3. Date of Earliest Transaction (Month/Day/Year) 09/23/2021									X	below) Chief Legal (below)		
(City)	AM MA						4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table	I - N	on-Deriva	tive S	Secur	rities	Ac	quire	d, Dis	sposed of	f, or E	Benefic	ially	Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y				Execution		on Date,		3. Transaction Code (Instr. 8)			Acquired (A) o (D) (Instr. 3, 4 a		and 5) Secu Bene		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price		Transa	iction(s) 3 and 4)			(3 4)	
Voting Common Stock 09/23/2			09/23/20	21			P		4,716	A	\$7.47	.4757(1)		4,716		D				
		Tal	ole II	- Derivati (e.g., pu						,	osed of, convertib			•	Owne	d				
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Exercise ce of ivative (Month/Day/Year) if any (Month/Day/Year)				5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		rative rities ired r osed) : 3, 4	Expir	ration D tth/Day/		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Der Sec (Ins	rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	

Explanation of Responses:

Remarks:

/s/ Zoran Zdraveski

09/27/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from \$7.43 to \$7.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.